IMG-7289, With and Without ATRA, in Patients With Advanced Myeloid Malignancies
Completed
Imago BioSciences,Inc.
Phase 1
This is a Phase 1 open label study of the dose and duration of an orally administered LSD1
inhibitor, IMG-7289, in patients with acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS). Some participants may also receive all-trans retinoic acid (ATRA; also known
as tretinoin and Vesanoid®) in combination with IMG-7289. This study investigates the
following:
- The safety and tolerability of IMG-7289, with and without ATRA
- The pharmacodynamic effect of different IMG-7289 doses and treatment durations, as well
as IMG-7289 administered in combination with ATRA
- The pharmacokinetics of IMG-2789, with and without ATRA
This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in
patients with myelofibrosis.
This study investigates the following:
- The safety and tolerability of IMG-7289
- The pharmacokinetics of IMG-7289 (performed in Phase 1/2a only)
- The pharmacodynamic effect of IMG-7289
This is a single-center, open-label investigator-initiated trial evaluating the effects of
IMG-7289 administered orally once daily in patients with essential thrombocythemia.
The University of Texas Health Science Center at San Antonio
Phase 2
This is a single-center, open-label investigator-initiated trial evaluating the effects of
IMG-7289 administered orally once daily in patients with essential thrombocythemia.
IMG-7289 in Patients With Essential Thrombocythemia
Recruiting
Imago BioSciences,Inc.
Phase 2
This is a Phase 2b open label study of an orally administered LSD1 inhibitor, IMG-7289, in
patients with essential thrombocythemia.
This study investigates the following:
- The safety and tolerability of IMG-7289
- The pharmacodynamic effect of IMG-7289
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
